Literature DB >> 8342321

Single capripoxvirus recombinant vaccine for the protection of cattle against rinderpest and lumpy skin disease.

C H Romero1, T Barrett, S A Evans, R P Kitching, P D Gershon, C Bostock, D N Black.   

Abstract

A recombinant capripoxvirus has been constructed containing a full-length cDNA of the fusion protein gene of rinderpest virus. The gene was inserted in the thymidine kinase gene of the capripox genome under the control of the vaccinia virus major late promoter p11 together with the Escherichia coli gpt gene in the opposite orientation under the control of the vaccinia early/late promoter p7.5. A vaccine prepared from this recombinant virus protected cattle against clinical rinderpest after a lethal challenge with a virulent virus isolate. In addition, the vaccine protected the cattle against lumpy skin disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8342321     DOI: 10.1016/0264-410x(93)90258-y

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Inhibition of in vitro leukocyte proliferation by morbilliviruses.

Authors:  J Heaney; T Barrett; S L Cosby
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine.

Authors:  Reuben K Soi; Fred R Rurangirwa; Travis C McGuire; Paul M Rwambo; James C DeMartini; Timothy B Crawford
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

Review 3.  Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

Authors:  B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

4.  Protection against myxomatosis and rabbit viral hemorrhagic disease with recombinant myxoma viruses expressing rabbit hemorrhagic disease virus capsid protein.

Authors:  S Bertagnoli; J Gelfi; G Le Gall; E Boilletot; J F Vautherot; D Rasschaert; S Laurent; F Petit; C Boucraut-Baralon; A Milon
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

5.  Myxoma virus leukemia-associated protein is responsible for major histocompatibility complex class I and Fas-CD95 down-regulation and defines scrapins, a new group of surface cellular receptor abductor proteins.

Authors:  Jean-Luc Guerin; Jacqueline Gelfi; Severine Boullier; Maxence Delverdier; Frederique-Anne Bellanger; Stephane Bertagnoli; Ingo Drexler; Gerd Sutter; Frederique Messud-Petit
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  Canine distemper virus (CDV) infection of ferrets as a model for testing Morbillivirus vaccine strategies: NYVAC- and ALVAC-based CDV recombinants protect against symptomatic infection.

Authors:  C B Stephensen; J Welter; S R Thaker; J Taylor; J Tartaglia; E Paoletti
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

Review 7.  The interference by maternally-derived antibody with active immunization of farm animals against foot-and-mouth disease.

Authors:  R P Kitching; J S Salt
Journal:  Br Vet J       Date:  1995 Jul-Aug

8.  MVA recombinants expressing the fusion and hemagglutinin genes of PPRV protects goats against virulent challenge.

Authors:  Dev Chandran; Kolli Bhaktavatsala Reddy; Shahana Pallichera Vijayan; Parthasarthy Sugumar; Gudavalli Sudha Rani; Ponsekaran Santha Kumar; Lingala Rajendra; Villuppanoor Alwar Srinivasan
Journal:  Indian J Microbiol       Date:  2010-03-16       Impact factor: 2.461

9.  Sheeppox virus kelch-like gene SPPV-019 affects virus virulence.

Authors:  C A Balinsky; G Delhon; C L Afonso; G R Risatti; M V Borca; R A French; E R Tulman; S J Geary; D L Rock
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

10.  Development of a dual recombinant vaccine to protect small ruminants against peste-des-petits-ruminants virus and capripoxvirus infections.

Authors:  G Berhe; C Minet; C Le Goff; T Barrett; A Ngangnou; C Grillet; G Libeau; M Fleming; D N Black; A Diallo
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.